NCT04948333 - Asciminib Treatment Optimization in ≥ 3rd Line CML-CP | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

March 12, 2024

Study Completion Date

February 3, 2026

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG

ABL001 40mg BID

One tablet of 40 mg will be taken orally twice a day (BID)

DRUG

ABL001 80mg QD

Two tablets of 40 mg will be taken orally once a day (QD)

DRUG

ABL001 200mg QD

Five tablets of 40 mg will be taken orally once a day (QD)

Trial Locations (48)

123

Novartis Investigative Site, Khoudh

1140

Novartis Investigative Site, Vienna

4010

Novartis Investigative Site, Linz

8036

Novartis Investigative Site, Graz

10450

Novartis Investigative Site, George Town

13353

Novartis Investigative Site, Berlin

15706

Novartis Investigative Site, Santiago Compostela

20900

Novartis Investigative Site, Monza

24116

Novartis Investigative Site, Kiel

28041

Novartis Investigative Site, Madrid

33076

Novartis Investigative Site, Bordeaux

34295

Novartis Investigative Site, Montpellier

37134

Novartis Investigative Site, Verona

38009

Novartis Investigative Site, Santa Cruz

41944

Novartis Investigative Site, Taegu

44093

Novartis Investigative Site, Nantes

48013

Novartis Investigative Site, Bilbao

60590

Novartis Investigative Site, Frankfurt am Main

68000

Novartis Investigative Site, Kuala Selangor

68305

Novartis Investigative Site, Mannheim

69373

Novartis Investigative Site, Lyon

75475

Novartis Investigative Site, Paris

80100

Novartis Investigative Site, Johor Bahru

80377

Novartis Investigative Site, München

88586

Novartis Investigative Site, Kota Kinabalu

100000

Novartis Investigative Site, Hanoi

119074

Novartis Investigative Site, Singapore

169608

Novartis Investigative Site, Singapore

738000

Novartis Investigative Site, Ho Chi Minh City

C1221ADC

Novartis Investigative Site, CABA

C1114AAN

Novartis Investigative Site, Buenos Aires

20211-030

Novartis Investigative Site, Rio de Janeiro

01236 030

Novartis Investigative Site, São Paulo

V5Z 1M9

Novartis Investigative Site, Vancouver

M5G 2M9

Novartis Investigative Site, Toronto

07740

Novartis Investigative Site, Jena

115 27

Novartis Investigative Site, Athens

570 10

Novartis Investigative Site, Thessaloniki

00161

Novartis Investigative Site, Roma

40-519

Novartis Investigative Site, Katowice

00-791

Novartis Investigative Site, Warsaw

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

LS9 7TF

Novartis Investigative Site, Leeds

CB2 0QQ

Novartis Investigative Site, Cambridge

SE1 9RT

Novartis Investigative Site, London

W12 0HS

Novartis Investigative Site, London